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ABSTRACT Trichoepithelioma is an uncommon benign adnexal neo-
plasm. It can present as a solitary non-familial or multiple familial form. 
Trichoepithelioma usually develops in early childhood or puberty. 
Females are more affected. It is attributed to two genetic mutations 
on chromosomes 9p21 and 16q12-q13. Multiple familial trichoepithe-
lioma is an autosomal-dominant disorder, characterized by numerous 
nodules and papules, predominantly on the face and occasionally on 
the scalp, neck, or upper trunk, positive family history, and histopatho-
logical findings. The lesions gradually increase in both size and number 
over time; however, they remain mostly asymptomatic. Although it is 
rare, trichoepithelioma lesions can undergo malignant transformation 
to trichoblastic carcinoma or basal cell carcinoma. Patients mainly seek 
treatment because the lesions are usually disfiguring and can lead to 
psycho-social issues. Non-pharmacologic approaches (e.g., excisional 
surgery, laser resurfacing), as the current mainstay of management, 
suffer from several drawbacks. New treatment techniques such as 
pharmacotherapy with potentially effective agents deserve more at-
tention and investigation.
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INTRODUCTION
Trichoepithelioma is a rare, benign tumor of the 
pilosebaceous unit that originates from the hair folli-
cles (1,2). It was first described almost simultaneously 
in 1892 in England by Brooke (3) as “epithelioma ad-
enoids cysticum” and in the United States by Fordyce 
(4) as “multiple benign cystic epithelioma”. Trichoepi-
thelioma can be divided into 3 subgroups including 
multiple familial trichoepithelioma (MFT), solitary 
non-hereditary trichoepithelioma, and desmoplas-
tic trichoepithelioma (5). MFT can also be present in 
Brooke-Spiegler syndrome (BSS) characterized by dif-
ferent combinations of inherited adnexal neoplasms 
including multiple trichoepitheliomas, cylindromas 
and occasional spiradenomas (6). Furthermore, other 
rare syndromes such as the Rombo syndrome (ver-
micular atrophoderma, milia, hypotrichosis,basal cell 
carcinomas, trichoepitheliomas and peripheral vaso-
dilatationwith cyanosis) and Basex syndrome (follicu-
lar atrophoderma, hypotrichosis, trichoepitheliomas, 
basal cell carcinomas, andhypohidrosis) can be asso-
ciated with MFT (7). Although the term trichoepithe-
lioma is still used in the literature, it is currently con-
sidered as a variant of tricoblastoma, a term that was 
coined in 1970, in the dermatopathology lexicon (8).
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Epidemiology
Trichoepithelioma is a rare cutaneous condition. 
Its exact prevalence is unknown. A dermatopathol-
ogy laboratory in the USA reported about 2.14 and 
2.75 cases of trichoepitheliomas in 9000 specimens 
per year (9). To the best of our knowledge, there is no 
official data about the frequency of trichoepithelio-
mas in Iran. Mapar et al. recently reported MFT in 6 
members in the family of an Arabian descent in three 
generations (10). Mohammadi and SeyedJafari also 
described a large family of Iranian origin with 15 indi-
viduals affected with MFT in four generations (11). Al-
though its pattern of inheritance is autosomal domi-
nant and both sexes receive equal genes, MFT seems 
to affect females more, probably due to smaller ex-
pressivity and chromosomal penetration in males 
(12). Cases of MFT typically arise in young to aging 
adults (9). However, MFT can first present in younger 
individuals aged between 10 and 20 years (13). Inter-
estingly, Carter et al. in 2007 reported the first case 
of congenital desmoplastic trichoepithelioma, pre-
senting with widespread erythematous plaques with 
milia-like lesions over the right scalp, face and neck in 
a girl born at term to a healthy mother (14). There is 
no racial predisposition to MFT (15).
ETIOLOGY
Two genetic mutations have been identified to 
be associated with MFT. The first one discovered is lo-
cated on the chromosomes 9p21 (16). Later, another 
mutation in the cylindromatosis tumor suppressor 
gene (CYLD) was found on the chromosome 16q12-
q13. The CYLD gene consists of 20 exons, of which 
three are un-translated, suggesting genetic hetero-
geneity of MFT. However, the MFT phenotype related 
to 9p21 is indistinguishable from that related to CYLD 
(17). BSS is also linked to the CYLD gene (6). Solitary 
trichoepithelioma has been linked to a gene at chro-
mosome 9q22.3 (2). As in BSS and familial cylindro-
matosis, individuals with CYLD-related MFT are born 
with one mutated copy of the CYLD gene in each cell 
(first hit). The second mutation or deletion of genetic 
material involving the other copy of the CYLD gene 
occurs in hair follicle cells, rather than in eccrine-apo-
crine cells observed in multiple cylindromas, during 
a person’s lifetime (second hit) (18). While this is not 
conclusive, some researchers believe that familial cyl-
indromatosis, BSS, and MFT are different phenotypic 
variables of a single entity (19). 
CYLD, a tumor suppressor gene, encodes a deu-
biquitinating enzyme that negatively regulates the 
activation of the nuclear factor κβ (NF-κβ) and c-Jun 
N-terminal kinase pathways (20). NF-κβ is a promi-
nent transcription factor involved in inflammation, 
immune response, oncogenesis, and apoptosis (21). 
Missense mutation in CYLD gene results in amino 
acid substitution within the ubiquitin-specific prote-
ase domain of CYLD protein, consequently dysregu-
lating the proliferation and differentiation of putative 
stem cells of the pilosebaceous-apocrine unit (5). 
During the recent decades, several novel muta-
tions in CYLD gene have been reported in either MFT 
or BSS within families of Algerian (17), Turkish (19), 
Israeli (22), Spanish (18), Taiwanese (23), or Chinese 
descents (24). According to the Genetics Home Ref-
erence database last reviewed in June 2012, at least 
20 CYLD germline mutations have been identified in 
individuals with BSS, more than 30 in subjects with 
familial cylindromatosis, and at least 22 in individuals 
with MFT (25). 
CLINICAL MANIFESTATIONS
MFT usually presents as multiple skin colored, 
pink, or bluish firm, rounded, translucent, shiny, well-
demarcated papules or nodules. The lesions locate 
Figure 1. Numerous skin-colored or pinkish, asymptomatic 
papules and nodules on the face (particularly in the peri-
nasal and chin areas) in two 17- and 25-year-old brothers. 
Their father and grandmother had similar lesions except for 
an ulcerated nodule in the peri-nasal area and an ulcerated, 
severely pruritic lesion on the forehead of the grandmoth-
er. Due to unbecoming appearance caused by facial skin le-
sions, the two brothers abandoned education and became 
shepherd. Details of multiple familial trichoepithelioma in 
this family have been recently published (10).
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dominantly on the face, particularly around the na-
solabial folds, nose, forehead, and eyelids. They are 
often symmetric on the face. Occasionally, the scalp, 
neck, and upper trunk can also be involved (2,15,20). 
The lesions are usually 2-5 mm in diameter (Figure 1). 
However, they may increase in size to up to 5 cm and 
2-3 cm on the face or ears and other sites, respective-
ly (15). Trichoepithelioma lesions may also gradually 
increase in number over years (2). The center of the 
lesions can be slightly depressed or umbilicated (15). 
There can be dilated (telangiectatic) blood vessels 
over the surface of large lesions (2,15). 
Trichoepithelioma lesions are without ulceration 
and there is no pruritus, so they are considered as-
ymptomatic (15). However, they can undergo the 
transformation into malignant neoplasms, such as 
trichoblastic carcinoma or basal cell carcinoma (BCC). 
Lee et al. briefly reviewed demographic and clinical 
characteristics of 12 cases of trichoblastic carcinomas 
arising from trichoepithelioma (26). According to a 
study by Pincus et al. (27), 6 reports describing 11 pa-
tients that evolved BCCs from MFT have been identi-
fied in the English language literature from 1959 to 
2008. Interestingly, cases of sporadic TEs associated 
with BCCs have also been reported. In 4 of the above 
reports, patients noticed the bleeding and/or ulcer-
ation at the site of the lesions (27). Mapar et al. (10) 
recently reported on a case of a 55-year-old woman 
presenting with slowly progressive, asymptomatic 
papules and nodules on her face for the last 37 years. 
She sought medical attention because one of her 
skin lesions became pruritic and ulcerated. The ulcer-
ated skin lesion was diagnosed as BCC derived from 
the trichoepithelioma, based on her history, physical 
examination, histopathological, and immunohisto-
chemistry findings (10). It has been advocated that 
clinicians should examine patients with MFT carefully 
and be much more vigilant about any rapid growth or 
ulceration in the pre-existing lesions as they are prob-
ably worrisome features of malignant transformation. 
Moreover, implementing preventive measures, such 
as optimal sunlight protection, are crucial in this re-
gards (27,28).
There are also occasional reports of MFT associa-
tion with other systemic disorders such as cerebellar 
infarction secondary to occlusion of the right poste-
rior inferior cerebellar artery in a 63-year old woman 
(29). Magnetic resonance imaging and angiography 
demonstrated a cerebellar aneurysm arising from the 
bifurcation of the middle cerebral artery along with 
right-subclavian pulmonary collateral vessels. Both 
her mother and uncle had died from subarachnoid 
hemorrhage (29). Other systemic abnormalities with 
MFT reported in the literature are as follows: malig-
nant lymphoepithelial lesion of the parotid gland 
(30), cheilognathopalatoschisis, jaw cysts, epilepsy, 
oligophrenia, bradykinesia, labyrinthine deafness, 
adipopositas, Dupuytren contracture, and micturi-
tion disturbance (29). Clinical relevance of these dis-
eases/disorders with MFT is unknown (31).
PATHOLOGY
Two major histopathological characteristics of 
MFT are horn cysts and tumor islands of basaloid 
cells. Horn cysts consist of fully keratinized centre sur-
rounded by basophilic cells. These cells lack atypia 
Table 1. Details of pharmacologic agents used for the management of trichoepitheliomas in 4 clinical studies
Reference Clinical setting Pharmacologic agents
Dose, Route and Duration of 
administration Efficacy
Van Voorst Vader 











in combination with 
tretinoin gel 1%
3 times a week and then, twice 
daily topically (Imiquimod) 
along with once a day topically 











325 mg twice a day orally 
(aspirin) along with 40 mg every 
other week for the first 2 months 
and thereafter, 40 mg every 
week as subcutaneous injection 




Alessiet al, 2009 
(52)
Trichoepitheliomas as a 
part of Brooke-Spiegler 
syndrome
Imiquimod cream 5%
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and mitosis. In contrast to the squamous cell carcino-
ma, keratinization in horn pearls is abrupt and com-
plete in MFT (5). Occasionally, primitive hair papillae, 
as well as hair shaft-like structures, can be observed 
in these central areas (2,20). The tumor islands are 
with peripheral palisading and increase in surround-
ing fibrous stroma (5). Tiny collections of mature se-
bocytes, as well as ductal differentiation may also be 
observed (20).
In small biopsies particularly, differentiating MFT 
vs. solitary trichoepithelioma from BCC can be very 
difficult (32). Histopathological findings in favor of 
trichoepithelioma over BCC are as follows: 1) symme-
try of the lesion and circumscription, 2) aggregations 
with smooth borders, 3) clefts between stroma (rath-
er than between epithelium and stroma), 4) absence 
of artifactual retraction between tumor cells and the 
surrounding stroma, 5) fibrocytic (rather than muci-
nous) stroma, 6) low mitotic activity, and 7) presence 
of mature’ follicular differentiation including well-
formed cornified cysts and papillary mesenchymal 
bodies (2,33,34).
Immunohistochemical staining technique might 
also distinguish between BCC and MFT. Antibodies 
against a number of immunomarkers such as CD34, 
bcl-2, androgen receptor, transforming growth factor-
β (TGF-β), and CD10 can be exploited in this regard 
(32). Furthermore, more recent studies have demon-
strated p75 neurotrophin receptor (p75NTR) (35) and 
pleckstrin homology-like domain, family A, member 1 
(PHLDA1) (36)as useful and practical adjuncts in differ-
ential diagnosis of MFT from BCC even in problematic 
cases (e.g. small skin biopsies). The diffuse pattern of 
bcl-2 staining in BCC lesions has been reported by at 
least 3 independent study groups (10,32,37). However, 
the reliability of bcl-2 in distinguishing MFT from BCC 
has been questioned by other studies (38,39). CD10 
demonstrated different staining patterns between 
MFT and BCC, basaloid versus stromal cells, respec-
tively, and therefore may be a favorable immunohis-
tochemical marker in differentiating MFT from BCC 
(40). However, in a case reported recently, only periph-
ery of basaloid cells in the BCC lesion showed strong 
CD10 immunoreactivity and it was entirely undetect-
able in trichoepithelioma lesions (10). Kirchmann et al. 
(41) and Illueca et al. (42) implicated CD34 expression 
in MFT rather than BCC lesions. This is in contrast to 
Mapar et al. findings of the lack of CD34 staining in 
both trichoepitheliomas and BCC lesions. Altogether, 
the immunomarkers bcl-2, CD10, and CD34 appears 
not to be helpful in differentiating BCC from MFT. 
However, evaluating the accuracy of relatively novel 
markers, such as androgen receptors, TGF-β, p75NTR, 
and PHLDA1, seems necessary in this matter (10).
TREATMENT
Although MFT is asymptomatic, affected patients 
mainly seek treatment for cosmetic concerns because 
the lesions are usually dense as well as disfiguring, 
and can lead to social isolation (15,28,43). Currently, 
no preventive measures are known (15). Excisional 
surgery is considered as the primary treatment ap-
proach (9). Other non-pharmacological treatment 
modalities that have been also tried include laser 
resurfacing (44-46), electro-surgery (43), cryosurgery 
(47), and dermabrasion (9). Regarding laser resurfac-
ing, Rallan and Harland demonstrated that the treat-
ment of trichoepitheliomas with erbium:Yag and CO2 
laser was associated with less scarrins and recurrence 
after 2 years compared to conventional treatments 
(48). Similarly, acceptable clinical response without 
considerable pain, bleeding, and postsurgical edema 
was also reported by CO2 laser treatment in two pa-
tients with multiple trichoepitheliomas on the face 
(49).
Plausible complications of non-pharmacological 
treatments include recurrence of the skin lesions, 
pain requiring local anesthetic injection, bleeding, 
scarring, and secondary skin cancer. Besides these 
pitfalls, some of the above approaches are time-con-
suming, costly, and inconvenient for patients (50). 
Based on the fact that MFT lesions may regress and 
become less obvious over time, and due to the com-
plications of non-pharmacological measures, some 
experts suggest a wait-and-watch approach along 
with assurance strategy (15,31). 
Due to the drawbacks of non-pharmacological 
therapies, pharmacotherapy has been also investi-
gated for MFT management. In a primary report, a 12-
week treatment with 1 mg/kg/day oral 13-cis-retinoic 
acid was found ineffective in a patient with multiple 
trichoepitheliomas and non-inflammatory cystic acne 
lesions on the face and neck (51). A Brazilian study of 
several types of cutaneous tumors reported that a 32-
week treatment with topical 5% imiquimod cream (5 
to 7 times per week) in 2 cases of trichoepitheliomas 
as part of BSS was associated with only partial clini-
cal response with the median follow up of 10 months 
(52). In another survey, about 80% of the lesions of 
an 11-year-old girl with multiple trichoepitheliomas 
were reversed by topical imiquimod cream (first 3 
times a week and then twice daily) and tretinoin gel 
1% (once daily) combination after 3 years, without 
scarring. The clinical superiority of the mentioned 
combination rather than imiquimod alone is justified 
by tretinoin’s ability to normalize epidermal turnover 
and therefore flattening of the thickness of the tricho-
epithelioma and enhancing imiquimod absorption. 
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(50). The therapeutic actions of imiquimod are attrib-
uted to promoting the maturation and secretion of 
tumor necrosis factor alpha (TNF-α) and interferon 
gamma (IFN-γ) and consequently, development of a 
Th1 lymphocyte-mediated immune response (50,52). 
Pharmacological agents with inhibitory effects on 
NF-κβ functions, such as corticosteroids and non-
steroidal anti-inflammatory drugs (NSAIDs) might be 
also potentially effective in the treatment of MFT (28). 
In this regards, Fisher and Geronemus reported a case 
of MFT recurrence in a 41-year-old white woman in 
spite of numerous laser resurfacing procedures for 15 
years (53). The patient achieved remarkable degree 
of improvement with a combination of oral aspirin 
(325 mg twice daily) and subcutaneous adalimumab 
(for the first 2 months, 40 mg every other week and 
thereafter, 40 mg every week) for 8 months. This com-
bination can block TNF-α-induced NF-κβactivation at 
2 levels (53). Table 1 summarizes the studied pharma-
cologic agents for the management of MFT. 
CONCLUSION
Trichoepithelioma can manifest as a solitary non-
familial or multiple familial type. MFT is a relatively 
rare, heritable, disfiguring, benign adnexal neoplasm 
that can be diagnosed by the centro-facial distribution 
pattern of papules and nodules, positive family histo-
ry, and related histopathological findings. Although 
very uncommon, MFT in a patient may develop and 
turn into BCC. Therefore, close clinical monitoring of 
affected patients for possible BCC transformation is 
crucial. Differentiating between MFT and BCCs is usu-
ally challenging and current immunohistochemical 
staining techniques appear to be of little value. Treat-
ment of MFT lesions only by the current non-phar-
macological modalities, such as excisional surgery, 
is usually difficult and can be associated with com-
plications. Pharmacotherapy option with potentially 
effective topical and systemic agents such as cortico-
steroids, NSAIDs, and anti-TNF-α (e.g., pentoxifylline, 
infliximab, etanercept) has been largely ignored and 
clinical studies are warranted in this area. 
References:
1.  Weedon D. Tumours of cutaneous appendages. 
In: Skin Pathology, 2nd edn. London: Churchill Li-
vingstone; 2002. pp.859-916.
2.  Calonje E. Tumors of the skin appendages. In: 
Burns T, Breathnach S, Cox N, Griffiths C (eds). 
Rook’s Textbook of Dermatology. Chichester: Wi-
ley-Blackwell, 2010. 
3. Brooke HG. Epitheliomaadenoidescysticum. Br J 
Dermatol. 1892;4:269-87.
4.  Fordyce JA. Multiple benign cystic epitheliomas 
of the skin. J Cutan Dis. 1892;10:459-73.
5.  Kataria U, Agarwal D, Chhillar D. Familial Facial 
disfigurement in Multiple Familial Trichoepithe-
lioma. J Clin Diagn Res. 2013;7:3008-9. 
6.  Bowen S, Gill M, Lee DA, Fisher G, Geronemus RG, 
Vazquez ME, et al. Mutations in the CYLD gene 
in Brooke-Spiegler syndrome, familial cylindro-
matosis, and multiple familial trichoepithelioma: 
lack of genotype-phenotype correlation. J Invest 
Dermatol. 2005;124:919-20.
7.  Szepietowski JC, Wasik F, Szybejko-Machaj G, Bi-
eniek A, Schwartz RA. Brooke-Spiegler syndrome. 
J Eur Acad Dermatol Venereol. 2001;15:346-9.
8.  Ackerman AB, Reddy VB, Soyer HP. Neoplasms 
with follicular differentiation. New York: Ardor 
Scribendi, 2001.
9.  Prieto VG, Shea CR. Trichoepithelioma. http://
emedicine.medscape.com/article/1060049-over-
view [Accessed on December 03, 2015].
10. Mapar MA, Ranjbari N, Afshar N, Karimzadeh I, Ka-
rimzadeh A. Severely disfiguring multiple familial 
trichoepitheliomas with basal cell carcinoma. In-
dian J Dermatol Venereol Leprol. 2014;80:349-52. 
11. Mohammadi AA, SeyedJafari SM. Trichoepithe-
lioma: a rare but crucial dermatologic issue. World 
J PlastSurg 2014;3:142-5.
12. Zheng G, Hu L, Huang W, Chen K, Zhang X, Yang 
S, et al. CYLD mutation causes multiple familial 
trichoepithelioma in three Chinese families. Hum 
Mutat. 2004;23:400.
13. Kaur T, Puri KJPS, Chahal KS, Budhwar J. Multiple 
Familial Trichoepitheliomas: A case report and 
review. Egyptian Dermatology Online Journal. 
2012;8:1-5.
14. Carter JJ, Kaur MR, Hargitai B, Brown R, Slator R, 
Abdullah A. Congenital desmoplastic trichoepit-
helioma. Clin Exp Dermatol. 2007;32:522-4. 
15. Bozi E, Katoulis AC. Multiple familial trichoepithe-
lioma. https://www.orpha.net/data/patho/GB/uk-
Trichoepithelioma.pdf [Accessed on December 
03, 2015].
16. Harada H, Hashimoto K, Ko MS. The gene for mul-
tiple familial trichoepithelioma maps to chromo-
some 9p21. J Invest Dermatol. 1996;107:41-3.
17. Salhi A, Bornholdt D, Oeffner F, Malik S, Heid E, 
Happle R, et al. Multiple familial trichoepithelioma 
caused by mutations in the cylindromatosis tumor 
suppressor gene. Cancer Res. 2004;64:5113-7.
18. España A, García-Amigot F, Aguado L, García-Fon-
cillas J. A novel missense mutation in the CYLD 
Karimzadeh et al. Acta Dermatovenerol Croat
Trichoepithelioma   2018;26(2):162-168
167ACTA DERMATOVENEROLOGICA CROATICA
gene in a Spanish family with multiple familial tric-
hoepithelioma. Arch Dermatol. 2007;143:1209-10.
19. Hu G, Onder M, Gill M, Aksakal B, Oztas M, Gürer 
MA, et al. A novel missense mutation in CYLD in 
a family with Brooke-Spiegler syndrome. J Invest 
Dermatol. 2003;121:732-4.
20. McCalmont TH. Adnexal Neoplasms. In: Bolognia 
JL, Jorizzo JL, Schaffer JV (eds). Dermatology, 3rd 
edn. China: Elsevier; 2012. pp. 1834.
21. Li Q, Verma IM. NF-kappaB regulation in the im-
mune system. Nat Rev Immunol 2002;2:725-34.
22. Reuven B, Margarita I, Dov H, Ziad K. Multiple tri-
choepitheliomas associated with a novel hetero-
zygous mutation in the CYLD gene as an adjunct 
to the histopathological diagnosis. Am J Derma-
topathol. 2013;35:445-7. 
23. Huang TM, Chao SC, Lee JY. A novel splicing muta-
tion of the CYLD gene in a Taiwanese family with 
multiple familial trichoepithelioma. Clin Exp Der-
matol. 2009;34:77-80. 
24. Qian F, Zhai Y, Yuan X, Li P, Wang W, Ding Y, et al. A 
novel mutation of CYLD gene in a Chinese family 
with multiple familial trichoepithelioma. Austra-
las J Dermatol. 2014;55:232-4. 
25. CYLD. http://ghr.nlm.nih.gov/gene/CYLD [Acces-
sed on December 03, 2015]. 
26. Lee KH, Kim JE, Cho BK, Kim YC, Park CJ. Malignant 
transformation of multiple familial trichoepitheli-
oma: case report and literature review. Acta Derm 
Venereol. 2008;88:43-6. 
27. Pincus LB, McCalmont TH, Neuhaus IM, Kasper 
R, Oh DH. Basal cell carcinomas arising within 
multiple trichoepitheliomas. J Cutan Pathol. 
2008;35:59-64. 
28. Yiltok SJ, Echejoh GO, Mohammad AM, Ituen AM, 
Igoche MI, Dades OT. Multiple familial trichoepit-
helioma: a case report and review of literature. Ni-
ger J Clin Pract. 2010;13:230-2.
29. Inatomi Y, Yonehara T, Fujioka S, Urata J, Ohyama 
K, Uchino M. Familial multiple trichoepithelioma 
associated with subclavian-pulmonary collateral 
vessels and cerebral aneurysm--case report. Neu-
rol Med Chir (Tokyo). 2001;41:556-60.
30. Autio-Harmainen H, Pääkkö P, Alavaikko M, Karvo-
nen J, Leisti J. Familial occurrence of malignant 
lymphoepithelial lesion of the parotid gland in a 
Finnish family with dominantly inherited tricho-
epithelioma. Cancer. 1988;61:161-6.
31. Crotty K, Dutta B, Hogan P. Multiple trichoepithe-
liomas in a mother and daughter. Australas J Der-
matol. 2003;44:270-2.
32. Poniecka AW, Alexis JB. An immunohistochemical 
study of basal cell carcinoma and trichoepithelio-
ma. Am J Dermatopathol. 1999;21:332-6.
33. Kechijian P, Connors RC, Ackerman AB. Trichoepit-
helioma vs. basal-cell carcinoma: criteria for histo-
logic differentiation. J Dermatol Surg. 1975;1:22-
3.
34. Ackerman AB, Reddy VB, Soyer HP. Neoplasms 
with follicular differentiation. New York: Ardor 
Scribendi, 2001.
35. Krahl D, Sellheyer K. p75 Neurotrophin receptor 
differentiates between morphoeic basal cell car-
cinoma and desmoplastic trichoepithelioma: in-
sights into the histogenesis of adnexal tumours 
based on embryology and hair follicle biology. Br 
J Dermatol. 2010;163:138-45.
36. Sellheyer K, Nelson P. Follicular stem cell marker 
PHLDA1 (TDAG51) is superior to cytokeratin-20 
in differentiating between trichoepithelioma and 
basal cell carcinoma in small biopsy specimens. J 
Cutan Pathol. 2011;38:542-50.
37. Verhaegh ME, Arends JW, Majoie IM, Hoekzema R, 
Neumann HA. Transforming growth factor-beta 
and bcl-2 distribution patterns distinguish tricho-
epithelioma from basal cell carcinoma. Dermatol 
Surg. 1997;23:695-700.
38. Swanson PE, Fitzpatrick MM, Ritter JH, Glusac EJ, 
Wick MR. Immunohistologic differential diagnosis 
of basal cell carcinoma, squamous cell carcinoma, 
and trichoepithelioma in small cutaneous biopsy 
specimens. J Cutan Pathol. 1998;25:153-9.
39. Abdelsayed RA, Guijarro-Rojas M, Ibrahim NA, 
Sangueza OP. Immunohistochemical evaluation 
of basal cell carcinoma and trichepithelioma 
using Bcl-2, Ki67, PCNA and P53. J Cutan Pathol. 
2000;27:169-75.
40. Heidarpour M, Rajabi P, Sajadi F. CD10 expression 
helps to differentiate basal cell carcinoma from 
trichoepithelioma. J Res Med Sci. 2011;16:938-44.
41. Kirchmann TT, Prieto VG, Smoller BR. CD34 staining 
pattern distinguishes basal cell carcinoma from 
trichoepithelioma. Arch Dermatol. 1994;130:589-
92.
42. Illueca C, Monteagudo C, Revert A, Llombart-Bo-
sch A. Diagnostic value of CD34 immunostaining 
in desmoplastic trichilemmoma. J Cutan Pathol. 
1998;25:435-9.
43. Shaffelburg M, Miller R. Treatment of multiple tri-
choepithelioma with electrosurgery. Dermatol 
Surg. 1998;24:1154-6.
44. Flores JT, Apfelberg DB, Maser MR, Lash H. Tricho-
Karimzadeh et al. Acta Dermatovenerol Croat
Trichoepithelioma   2018;26(2):162-168
168
epithelioma: successful treatment with the argon 
laser. Plast Reconstr Surg. 1984;74:694-8.
45. Rosenbach A, Alster TS. Multiple trichoepithe-
liomas successfully treated with a high-energy, 
pulsed carbon dioxide laser. Dermatol Surg. 
1997;23:708-10.
46. Yong AA, Goh CL. Successful treatment of a large 
solitary nasal tip trichoepithelioma using the 
10,600-nm carbon dioxide laser. Dermatol Surg 
2015;41:528-30. 
47. Duhra P, Paul JC. Cryotherapy for multiple trichoe-
pithelioma. J Dermatol Surg Oncol. 1988;14:1413-
5.
48. Rallan D, Harland CC. Brooke-Spiegler syndrome: 
treatment with laser ablation. Clin Exp Dermatol. 
2005;30:355-7.
49. Retamar RA, Stengel F, Saadi ME, Kien MC, Della 
Giovana P, Cabrera H, et al. Brooke-Spiegler syn-
drome - report of four families: treatment with 
CO2 laser. Int J Dermatol. 2007;46:583-6.
50. Urquhart JL, Weston WL. Treatment of multiple 
trichoepitheliomas with topical imiquimod and 
tretinoin. Pediatr Dermatol. 2005;22:67-70.
51. Van Voorst Vader PC, Van Oostveen F, Hasper MF. 
Trichoepithelioma, cystic acne and 13-cis-retinoic 
acid. Acta Derm Venereol. 1984;64:360-1.
52. Alessi SS, Sanches JA, Oliveira WR, Messina MC, Pi-
mentel ER, Festa Neto C. Treatment of cutaneous 
tumors with topical 5% imiquimod cream. Clinics 
(Sao Paulo). 2009;64:961-6. 
53. Fisher GH, Geronemus RG. Treatment of multiple 
familial trichoepitheliomas with a combination of 
aspirin and a neutralizing antibody to tumor ne-
crosis factor alpha: A case report and hypothesis 
of mechanism. Arch Dermatol. 2006;142:782-3.
Karimzadeh et al. Acta Dermatovenerol Croat
Trichoepithelioma   2018;26(2):162-168
ACTA DERMATOVENEROLOGICA CROATICA
